The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 7, 2011, Pages 1603-1614

  Bhandari, Dilli Ram ^a,b   Seo, Kwang Won ^a,b   Jung, Ji Won ^a,b   Kim, Hyung Sik ^a,b   Yang, Se Ran ^a,b   Kang, Kyung Sun ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

C MYC; Differentiation; HDAC2; HMSCs; PcG; Proliferation; Stem cell

Indexed keywords

HISTONE DEACETYLASE 2; MYC PROTEIN; POLYCOMB GROUP PROTEIN; REPRESSOR PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MULTIPOTENT STEM CELL; PHYSIOLOGY; PROMOTER REGION;

CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 2; HUMANS; MULTIPOTENT STEM CELLS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 79959483123     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01144.x     Document Type: Article

References (54)

1. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008; 132: 567-82.
2. Campagnoli C, Roberts IA, Kumar S, et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001; 98: 2396-402.
3. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000; 109: 235-42.
4. Gronthos S, Franklin DM, Leddy HA, et al. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol. 2001; 189: 54-63.
5. Igura K, Zhang X, Takahashi K, et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy. 2004; 6: 543-53.
6. Tsai MS, Lee JL, Chang YJ, et al. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004; 19: 1450-6.
7. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000; 2: 477-88.
8. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276: 71-4.
9. Pittenger M, Vanguri P, Simonetti D, et al. Adult mesenchymal stem cells: potential for muscle and tendon regeneration and use in gene therapy. J Musculoskelet Neuronal Interact. 2002; 2: 309-20.
10. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999; 103: 697-705.
11. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des. 2005; 11: 1255-65.
12. Tropel P, Platet N, Platel JC, et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells. 2006; 24: 2868-76.
13. Bhatia R, Hare JM. Mesenchymal stem cells: future source for reparative medicine. Congest Heart Fail. 2005; 11: 87-91.
14. Grandori C, Cowley SM, James LP, et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16: 653-99.
15. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6: 635-45.
16. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol. 2006; 16: 242-52.
17. Knoepfler PS, Zhang XY, Cheng PF, et al. Myc influences global chromatin structure. EMBO J. 2006; 25: 2723-34.
18. Sumi T, Tsuneyoshi N, Nakatsuji N, et al. Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc. Oncogene. 2007; 26: 5564-76.
19. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007; 448: 445-51.
20. Bhandari DR, Seo K, Roh K, et al. REX-1 expression and p38 MAPK activation status can determine proliferation/differentiation fates in human mesenchymal stem cells. PLoS ONE. 2010; 5: e10493.
21. Nagai A, Kim WK, Lee HJ, et al. Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow. PLoS ONE. 2007; 2: e1272.
22. Grandori C, Wu KJ, Fernandez P, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003; 17: 1569-74.
23. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res. 2003; 283: 17-21.
24. Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol. 2008; 33: 375-80.
25. Gao L, Cueto MA, Asselbergs F, et al. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002; 277: 25748-55.
26. Wolffe AP. Histones, nucleosomes and the roles of chromatin structure in transcriptional control. Biochem Soc Trans. 1997; 25: 354-8.
27. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998; 391: 597-601.
28. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001; 10: 693-8.
29. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007; 18: 769-74.
30. Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5: 455-63.
31. Humphrey GW, Wang YH, Hirai T, et al. Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation. 2008; 76: 348-56.
32. Jung JW, Lee S, Seo MS, et al. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci. 67: 1165-76.
33. Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002; 16: 2893-905.
34. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell. 2004; 118: 409-18.
35. Levine SS, Weiss A, Erdjument-Bromage H, et al. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol. 2002; 22: 6070-8.
36. Rajasekhar VK, Begemann M. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells. 2007; 25: 2498-510.
37. Frye M, Fisher AG, Watt FM. Epidermal stem cells are defined by global histone modifications that are altered by Myc-induced differentiation. PLoS ONE. 2007; 2: e763.
38. Seo KW, Lee SR, Bhandari DR, et al. OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs). Biochem Biophys Res Commun. 2009; 384: 120-5.
39. Park JR, Jung JW, Lee YS, et al. The roles of Wnt antagonists Dkk1 and sFRP4 during adipogenesis of human adipose tissue-derived mesenchymal stem cells. Cell Prolif. 2008; 41: 859-74.
40. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol. 2009; 482: 281-94.
41. Okamoto T, Aoyama T, Nakayama T, et al. Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun. 2002; 295: 354-61.
42. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med. 2002; 8: 1105-14.
43. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9: 1149-63.
44. Ogawa T, Yogo K, Ishida N, et al. Synergistic effects of activin and FSH on hyperphosphorylation of Rb and G1/S transition in rat primary granulosa cells. Mol Cell Endocrinol. 2003; 210: 31-8.
45. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000; 183: 10-7.
46. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999; 18: 1571-83.
47. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci. 2009; 66: 236-53.
48. Takada I, Suzawa M, Matsumoto K, et al. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci. 2007; 1116: 182-95.
49. Yamashiro T, Wang XP, Li Z, et al. Possible roles of Runx1 and Sox9 in incipient intramembranous ossification. J Bone Miner Res. 2004; 19: 1671-7.
50. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003; 17: 1115-29.
51. Studzinski GP. Oncogenes, growth, and the cell cycle: an overview. Cell Tissue Kinet. 1989; 22: 405-24.
52. Niessen HE, Demmers JA, Voncken JW. Talking to chromatin: post-translational modulation of polycomb group function. Epigenetics Chromatin. 2009; 2: 10.
53. Guney I, Sedivy JM. Cellular senescence, epigenetic switches and c-Myc. Cell Cycle. 2006; 5: 2319-23.
54. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009; 50: 455-63.